Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ricky, we must be using the same stock screens, just stumbled on this one - looks like you're in. i am considering ...
Started new position here last few days. My DD looks decent. I'm a person who buys a position for trading and for keeping a core position. I will trade the ups and downs. Goal is always to have a decent core position paid for in full with the money I make for trading.
Looking forward to seeing what is going on here. I think this has a chance of a 2x to 5x increase in the next year.
Strong close and volume..
BBI
Approval in Sept product launch November this co. has an awesome Japanese partner moving at light speed
I am currently waiting for some free’d up cash to buy back in over here. See if she dips a bit then it should make a rather quick move back up over a dollar to comply with the Nasdaq warning. I think in two more days kaken can officially start selling ecclock in Japan.
https://www.globenewswire.com/news-release/2020/11/18/2129056/0/en/Brickell-Biotech-Announces-Launch-Date-for-Sofpironium-Bromide-Gel-5-ECCLOCK-in-Japan-by-its-Development-Partner-Kaken-Pharmaceutical.html
Hopefully next financials for brickell will reflect that as well. Also they are finalizing their trials in the states which passed in Japan, so hopefully smooth sailing over here to get it in the U.S. market.
https://ir.brickellbio.com/news/detail/38/brickell-biotech-announces-initiation-of-u-s-phase-3
https://ir.brickellbio.com/news/detail/41/brickell-biotech-reports-third-quarter-2020-financial
-IMO HUGE UPSIDE POTENTIAL OVER HERE-
-BBI
Looking forward to hearing something positive!
-BBI
BBI Earnings day 12th November, on watch!
Sold my position over here before the new price offering announcement.
https://ir.brickellbio.com/news/detail/39/brickell-biotech-announces-pricing-of-15-0-million
Read it in the 8K, I guess this company is using the reasoning of these new tests they are starting up to do another price offering 3 and a half months after they did the last one for 20 million worth..
https://ir.brickellbio.com/news/detail/31/brickell-biotech-inc-announces-pricing-of-20-1-million
Before they could even try and get their pps above a dollar to meet the warning letter of delisting to the otc
https://www.google.com/amp/s/www.dailycamera.com/2020/08/24/brickell-biotech-gets-delisting-notice-from-nasdaq/amp/
So why do they just keep running their pps in to the ground?
There are really two outcomes I can see happening, either the company doesn’t give a sh*t anymore and see you in the otc, or they are sitting on something that is going to push this to stay over a dollar and will release it sometime between now and the time given for the delisting.
If you look at all of the recent stock acquisitions by the people that run the company, most are purchasing shares around .80 pps average. So if they knew by releasing this offering a month after they bought stock for a third higher than its trading after the offering. They are either throwing their money away, or they know it will be higher very soon..
I am considering taking another position but staying on the sidelines for now. Good luck to everyone!
-BBI
https://dbtnews.com/2020/10/28/brickell-biotech-inc-bbi-fell-65-33-so-far-this-year-what-now/
My god! What is this company doing to its pps? There going to get delisted and put on the otc soon if they keep this sh*t up!
-BBI
I understand that in theory. But they just diluted the stock around 17.5 million worth just around 2 months ago.. That was supposed to be for R&D, manufacturing, etc.. Now all of a sudden another offering... Also in their disclaimer it says they have never ran a phase 3 trial before... “high risk investment” is the terminology they use.. word for word.. Plus they got a delisting warning letter . If their pps doesn’t get up above a $1 and stay there we will be in the otc... Plus they owe Kaken all kinds of money and it could possibly void BBI’s royalties.. Either way I can go on and on and if you do about 15-30 minutes of research you would find everything I have said verbatim plus a decent bit more.. I bought in here at $1.27 then they did the offering and announced it late at night, around 10 or 10:30 EST which is BS but it is what it is.. Then PPS went under a dollar so I averaged down to around $1.07 and literally sat here for around the months... Every time they did release something good it was to push those shares. Churn’em out baby.. F the shareholders that paid way more than me earlier that day. I was stuck but a lot more people got stuck worse than me because I had bought low of the day. It had went to around $1.70 I think. I was all in on this one but I finally just took a 15-20% hit so I could have some liquidity to get in on some other plays and just watch this. Thinking loading zone over here is going to be in the .70’s again real soon if not test a new low especially since we have to wait in till end of the year probably for any news from Japan or if BBI got thru their phase 3 without f-ing up.. Anyways good luck to you!
-BBI
The 15 mil will help bring the product to market.
Every time the pps starts to take off, they just release more sh*t to lower it back down again... Sold at the beginning of the week. Will keep my eyes on this play, but definitely from the sidelines, and definitely not long term at the moment. Per their latest securities statement release 15,000,000 seems to be the new dilution number of the month! Keep this sh*t up and BBI will be trading on the otc!
-BBI
Scroll down to the actual article once you click the link
https://www.reportdoor.com/fast-money-traders-share-their-thoughts-on-att-coca-cola/
-BBI
Anges has been doing the coronavirus vaccine since the virus started. Obviously they are on the right track for them to want to get involved with brickell! Anges net worth over 2.5 billion!
https://www.google.com/amp/s/financialpost.com/pmn/business-pmn/pharma-firm-anges-and-osaka-university-to-begin-testing-coronavirus-vaccine-on-animals-2/wcm/c40f9f02-ac76-474a-abab-794d576d4ba9/amp/
-BBI
Interesting article. It seems Anges has been primed on having a vaccine ready by end of year.
https://www.google.com/amp/s/www.nasdaq.com/articles/anges-brickell-ink-deal-to-develop-dna-vaccine-candidate-for-covid-19-quick-facts-2020-09%3famp
-BBI
It will be for sale in Japan. Revenue coming in for brickell!
https://m.marketscreener.com/quote/stock/KAKEN-PHARMACEUTICAL-CO--6493413/news/Kaken-Pharmaceutical-ECCLOCK-Gel-5-Approved-in-Japan-for-the-Treatment-of-Primary-Axillary-Hyper-31357866/
-BBI
Sad state of affairs over here.. Company has been diluting the stock so much when the news comes out we have been waiting for over 2 months pps doesn’t even break a dollar! Better figure something out to get this over the dollar mark to stay or delisting is next! Hopefully this is the start of a nice climb, but I am not holding my breath! It seems as though all of the people working for this company has been buying up a lot of shares so hopefully that is a good sign!
-BBI
VERY NICE CANDLES, closing above moving averages..
Could be making a major run next week.. imo
I have a good feeling and position here.
Brickell Biotech Announces Approval of Sofpironium Bromide Gel, 5% in Japan for Treatment of Primary Axillary Hyperhidrosis Received by its Development Partner, Kaken Pharmaceutical
Japan is the first country to approve sofpironium bromide with commercial launch expected later this year
----------------
Brickell is on track to initiate its U.S. pivotal Phase 3 program for sofpironium bromide in Q4 2020
BOULDER, CO — September 25, 2020 —Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases, announced today that its Japanese development partner, Kaken Pharmaceutical Co., Ltd. (“Kaken”), received approval to manufacture and market sofpironium bromide gel, 5% under the brand name ECCLOCK® in Japan for the treatment of primary axillary (underarm) hyperhidrosis.
“We are thrilled with the Japanese approval of sofpironium bromide, which is the first topical prescription product to be approved in Japan for the treatment of primary axillary hyperhidrosis,” commented Robert Brown, Chief Executive Officer of Brickell. “This is a significant milestone for Brickell and Kaken, as Kaken can now focus its efforts on the commercial launch of sofpironium bromide gel in Japan, which is expected to occur later this year. Most importantly, this novel, first-in-class therapy will soon be available to help improve the quality of life for Japanese patients suffering from this debilitating condition.”
This regulatory approval is based on the results of the Japanese Phase 3 pivotal registration study of sofpironium bromide gel, 5% in 281 patients with primary axillary hyperhidrosis, in which all primary and secondary efficacy endpoints demonstrated statistically significant differences between sofpironium bromide gel and vehicle (placebo). In addition, sofpironium bromide gel was deemed to be safe and generally well tolerated in this study, as well as in the accompanying 52-week long-term safety extension study in Japan.
Under the sublicense agreement with Kaken, Brickell is entitled to receive sales-based milestone payments, as well as tiered royalties based on a percentage of net sales of sofpironium bromide gel in Japan. Importantly, Kaken has rights to develop and commercialize sofpironium bromide in Korea, China and certain other Asian countries, and will now turn its attention to these markets.
Sofpironium bromide is currently being developed by Brickell in the U.S. for the treatment of primary axillary hyperhidrosis. Brickell is on track to initiate its pivotal Phase 3 program in the U.S. for sofpironium bromide gel, 15% during the fourth quarter of 2020, which will ultimately be comprised of two pivotal Phase 3 trials to evaluate sofpironium bromide gel compared to vehicle in approximately 350 subjects (per trial) with primary axillary hyperhidrosis.
About Sofpironium Bromide
Sofpironium bromide is a proprietary new chemical entity that belongs to a class of medications called anticholinergics. Anticholinergics block the action of acetylcholine, a chemical that transmits signals within the nervous system that are responsible for a range of bodily functions, including activation of the sweat glands. Sofpironium bromide was retrometabolically designed. Retrometabolic drugs are designed to exert their action topically and are potentially rapidly metabolized into a less active metabolite once absorbed into the blood. This proposed mechanism of action may allow for highly effective doses to be used while limiting systemic side effects. Sofpironium bromide was discovered at Bodor Laboratories, Inc. by Dr. Nicholas Bodor D.Sc., d.h.c. (multi), HoF, Graduate Research Professor Emeritus, University of Florida. Sofpironium bromide is not approved for use in any country at this time.
About Hyperhidrosis
Hyperhidrosis is a life-altering medical condition where a person sweats more than the body requires to regulate its temperature. More than 15 million people, or 4.8% of the population of the United States, and 12.7% of the population in Japan, are believed to suffer from hyperhidrosis1,2. Primary axillary (underarm) hyperhidrosis is the targeted first indication for sofpironium
bromide and is the most common site of occurrence of hyperhidrosis, affecting an estimated 65% of patients with hyperhidrosis in the United States or 10 million individuals and an estimated 45% of patients with hyperhidrosis in Japan1,2. Additional information can be found on the International Hyperhidrosis Society website: https://www.sweathelp.org/.
About Brickell
Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on developing innovative and differentiated prescription therapeutics for the treatment of debilitating skin diseases. Brickell’s pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell’s executive management team and board of directors bring extensive experience in product development and global commercialization, having served in leadership roles at large global pharmaceutical companies and biotechs that have developed and/or launched successful products, including several that were first-in-class and/or achieved iconic status, such as Cialis®, Taltz®, Gemzar®, Prozac®, Cymbalta® and Juvederm®. Brickell’s strategy is to leverage this experience to in-license, acquire, develop and commercialize innovative products that Brickell believes can be successful in the currently underserved dermatology global marketplace. For more information, visit https://www.brickellbio.com.
Cautionary Note Regarding Forward-Looking Statements
Any statements made in this press release relating to future financial, legal, business and/or research and clinical performance, conditions, plans, prospects, trends, or strategies and other such matters, including without limitation, the anticipated timing, scope, design and/or results of future clinical trials, intellectual property rights, including the validity, term and enforceability of such, the expected timing and/or results of regulatory approvals and prospects for commercializing any of Brickell’s product candidates, or research collaborations with its partners, including in Japan, the United States or any other country, are forward- looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Brickell, may identify forward-looking statements. Brickell cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time, often quickly and in unanticipated ways. Important factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including without limitation, ability to obtain adequate financing to advance product development, ability to maintain and enforce intellectual property rights, potential delays for any reason in product development, regulatory changes, unsuccessful clinical trials, unanticipated demands on cash resources, any disruption to our business caused by the current COVID-19 pandemic, interruptions, disruption or inability to launch and commercialize the product by Kaken in Japan, or obtain adequate pricing approval, and other risks associated with developing and obtaining regulatory approval for and commercializing product candidates.
Further information on the factors and risks that could cause actual results to differ from any forward-looking statements are contained in Brickell’s filings with the United States Securities and Exchange Commission (SEC), which are available at www.sec.gov (or at https://www.brickellbio.com). The forward-looking statements represent the estimates of Brickell as of the date hereof only, and Brickell specifically disclaims any duty or obligation to update forward-looking statements.
1Doolittle et al. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res 2016; 308: 743-749.
2Fujimoto et al. Epidemiological study and considerations of focal hyperhidrosis in Japan. J Dermatol 2013; 40: 886-90.
Brickell Investor Contact:
Dan Ferry
LifeSci Advisors
(617) 430-7576
daniel@lifesciadvisors.com
Here is a link to AnGes inc. showing a news release this morning in Japan!
https://www.anges.co.jp/en/news/index.php
-BBI
This just released an hour ago!
https://m.marketscreener.com/quote/stock/ANGES-INC-6814797/news/AnGes-COVID-19-DNA-vaccine-development_Announcement-of-Collaboration-Agreement-with-Brickell-Biote-31249142/
-BOOM-
-BBI
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
167
|
Created
|
02/18/20
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |